论文部分内容阅读
探讨肿瘤标记物癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、CA72-4、细胞角质蛋白19片段(CYFR21-1)和鳞状上皮细胞癌抗原(SCC)联合检测对食管癌诊断、治疗及预后判断的临床价值。用电化学发光免疫分析法(ECLIA)检测88例食管癌患者术前和72例术后血清中CEA、CA19-9、CA72-4、CYFRA21-1和SCC含量。148例食管癌患者血清中5项肿瘤标记物含量均明显高于对照组,随病情增加,阳性率增高。检测102例食管癌患者,术前阳性指标与术后比较,有显著性差异(P<0.01)。五项肿瘤标志物联合检测阳性率为77.5%,高于单项指标检测阳性率,有显著性差异(P<0.01)。血清CEA、CA19-9、CA72-4、CYFRA21-1和SCC水平动态联合检测可用于食管癌辅助诊断、疗效观测,以及对病情及预后的判断。
(CEA), carbohydrate antigen 19-9 (CA19-9), CA72-4, CYFR21-1 and squamous cell carcinoma antigen (SCC) Clinical Value of Diagnosis, Treatment and Prognosis of Esophageal Cancer. The levels of CEA, CA19-9, CA72-4, CYFRA21-1 and SCC in 88 patients with esophageal cancer before and after the operation were detected by electrochemiluminescence immunoassay (ECLIA). 148 cases of esophageal cancer serum 5 tumor markers were significantly higher than the control group, with the disease increased, the positive rate increased. The detection of 102 cases of esophageal cancer patients, preoperative positive indicators and postoperative comparison, there was a significant difference (P <0.01). The positive rate of five tumor markers was 77.5%, which was higher than the positive rate of single index (P <0.01). Serum CEA, CA19-9, CA72-4, CYFRA21-1 and SCC levels of dynamic joint detection of esophageal cancer can be used for auxiliary diagnosis, the efficacy of observation, as well as the disease and prognosis.